Anti-Rac1 (23A8) and anti-β-actin (MAB 1501) monoclonal antibodies were purchased from [Upstate Biotechnology and Chemicon International, respectively (now Merck KGaA, and its affiliates), Darmstadt, Germany]. Both the anti-JNK and anti-phospho-JNK (Thr183/Tyr185) polyclonal antibodies were purchased from R&D Systems, Inc. (Minneapolis, MN, USA). E-cadherin (36/E-Cadherin) and N-cadherin (32/N-Cadherin) were obtained from BD Biosciences (Becton Dickinson, Franklin Lakes, New Jersey, USA). Cytokeratin (AE1/3) and vimentin (V9) were purchased from Dako Agilent Technologies, Inc. (Santa Clara, CA, USA). Secondary antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). NSC23766 and SP600125 were purchased from Tocris Bioscience (Bristol, UK). The complementary DNA (cDNA) of the dominant negative N17Rac1 (Rac-DN), which encoded for a mutated amino acid 17 from Thr to Asn was provided by Dr. A. Hall (University College London, Laboratory for Molecular Cell Biology, UK). The expression plasmid was constructed as previously described [22].

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.